

Kidney Biopsy: The Most Reliable Way to Detect Kidney Cancer

David Forrsee*

Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway

***Corresponding author:** David Forrsee, Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway, E-mail: forrsee.david@med.uib.no

Received: 01-May-2023, Manuscript No: jcd-23-98357, **Editor Assigned:**

or therapy strategies for RCC. The majority of traditional M2 markers (CD206, CD163) or the pan-macrophage marker CD68 has been used to measure macrophages in RCC to date. Nevertheless, employing these markers for a simple quantification of macrophages is insufficient for predicting the clinical course of the disease and may potentially be misleading given that CD68 was demonstrated to be expressed by ccRCC cells. These markers can be combined to develop a novel diagnostic approach with outstanding predictive ability.

They use markers like CD204, CD206, or folate receptor beta, which aren't particularly selective for macrophages that are linked with tumours and are even less so for a particular kind of tumour. For the purpose of finding TAM markers that are specific to tumours, screening tests must be carried out. The results of these screens will make it possible to create targeting methods for reprogramming or eradicating TAM populations that sustain tumours.

Acknowledgement

None

Conflict of Interest

None

References

1. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, et al. (2008) BRAF(V600E) mutation and the biology of papillary thyroid cancer. *Endocr Relat Cancer* 15: 191-205.
2. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, et al. (2003) RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid